Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer

Modern Pathology

Volumn 28, Issue 5, 2015, Pages 677-685

  Gökmen Polar, Yesim ^a   Neelamraju, Yaseswini ^a   Goswami, Chirayu P ^a   Gu, Xiaoping ^a   Nallamothu, Gouthami ^a   Janga, Sarath Chandra ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PARAFFIN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA, HUMAN; RNA BINDING PROTEIN; SF3B3 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LOW RISK POPULATION; MCF 7 CELL LINE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLICING FACTOR 3B SUBUNIT 1 GENE; TUMOR GENE; UPREGULATION; VALIDATION STUDY; BIOSYNTHESIS; BREAST TUMOR; DRUG RESISTANCE; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA-BINDING PROTEINS; TRANSCRIPTOME; UP-REGULATION;

EID: 84928827432     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.146     Document Type: Article

References (32)

1. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep. 2008; 9: 1087-1093
2. Yoshida K, Ogawa S. Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA. 2014; 5: 445-459
3. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011; 118: 6239-6246
4. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491: 399-405
5. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70
6. Harbour JW, Roberson ED, Anbunathan H, et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013; 45: 133-135
7. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365: 2497-2506
8. Furney SJ, Pedersen M, Gentien D, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013; 3: 1122-1129
9. Quesada V, Ramsay AJ, Lopez-Otin C. Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med. 2012; 366: 2530
10. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012; 486: 353-360
11. Das BK, Xia L, Palandjian L, et al. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol Cell Biol. 1999; 19: 6796-6802
12. Kramer A, Gruter P, Groning K, et al. Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP. J Cell Biol. 1999; 145: 1355-1368
13. Will CL, Schneider C, MacMillan AM, et al A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site. EMBO J 2001; 20: 4536-4546
14. Will CL, Urlaub H, Achsel T, et al. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J 2002; 21: 4978-4988
15. Yokoi A, Kotake Y, Takahashi K, et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J 2011; 278: 4870-4880
16. Kotake Y, Sagane K, Owa T, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007; 3: 570-575
17. Hungermann D, Schmidt H, Natrajan R, et al. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol. 2011; 224: 517-528
18. Brunner N, Frandsen TL, Holst-Hansen C, et al. MCF7/.LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993; 53: 3229-3232
19. Brunner N, Boysen B, Jirus S, et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997; 57: 3486-3493
20. Ringner M, Fredlund E, Hakkinen J, et al. GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011; 6: e17911
21. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752
22. Paik S, Shak S, Tang G, et al A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826
23. Davies C, Pan H, Godwin J, et al. Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805-816
24. Gray RG, Rea D, Handley K, et al. aTTom: Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31: 5
25. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62: 233-247
26. Rymond B. Targeting the spliceosome. Nat Chem Biol. 2007; 3: 533-535
27. Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012; 11: 847-859
28. Fan L, Lagisetti C, Edwards CC, et al. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol. 2011; 6: 582-589
29. Albert BJ, McPherson PA, O'Brien K, et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther. 2009; 8: 2308-2318
30. Lagisetti C, Pourpak A, Goronga T, et al. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. J Med Chem. 2009; 52: 6979-6990
31. Hong DS, Kurzrock R, Naing A, et al A phase I, openlabel, single-Arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2013; 32: 436-444
32. Dehm SM. Test-firing ammunition for spliceosome inhibition in cancer. Clin Cancer Res. 2013; 19: 6064-6066